• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Biotech

    Compass Therapeutics To Release Phase 2/3 Tovecimig Study

    GLOBENEWSWIRE

    Compass Therapeutics Reveals 2025 Financials And Corporate Update

    GLOBENEWSWIRE

    Compass Therapeutics Provides Corporate Update

    GLOBENEWSWIRE

    Compass Therapeutics Joins December Investor Conference

    GLOBENEWSWIRE

    Compass Therapeutics Reveals Q3 2025 Financials & Corporate

    GLOBENEWSWIRE

    Compass Therapeutics Unveils CTX-10726, Data At SITC Meeting

    GLOBENEWSWIRE

    Compass Therapeutics Joins November Investor Events

    GLOBENEWSWIRE

    Compass Therapeutics to Join September Investor Events

    GLOBENEWSWIRE

    Compass Therapeutics Reports Q1 2025 Financials and Update

    GLOBENEWSWIRE

    Compass Therapeutics to Join May Investor Events

    GLOBENEWSWIRE

    Compass Therapeutics Presents Data on CTX-471 at AACR Meeting

    GLOBENEWSWIRE

    Compass Therapeutics: First Patient Dosed in Tovecimig Trial

    GLOBENEWSWIRE

    Tovecimig (CTX-009) Meets Primary Endpoint in Biliary Tract Cance

    GLOBENEWSWIRE

    Compass Webcast on Tovecimig Study in Biliary Tract Cancer

    GLOBENEWSWIRE

    Compass To Participate in Guggenheim Biotech Conference

    GLOBENEWSWIRE

    Compass Therapeutics Biomarker Data on CTX-471 at 39th SITC

    GLOBENEWSWIRE

    Compass Ctx-471 Phase 1 Data: Cd137 Antitumor In Pd-(L)1 Progressive

    GLOBENEWSWIRE

    Compass gets US FDA fast track for its bispecific DLL4/VEGF-A antibody, CTX-009

    PHARMABIZ

    Compass Gets FDA Fast Track For CTX-009 + Pacli in Pre-Treated Biliary Cancer

    GLOBENEWSWIRE

    Compass begins patient dosing in phase 1 study of CTX-8371 solid tumours

    PHARMABIZ

    Compass Announces Publication of CTX-8371 Preclinical Data in OncoImmunology

    GLOBENEWSWIRE

    Compass Announces that the PII Data of CTX-009 in Combination with Paclitaxel

    GLOBENEWSWIRE

    Compass Announces First Patient Dosed in the Phase 2 U.S. Study of CTX-009

    GLOBENEWSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.